PeptideSearch

Selank

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2024-09-27

Also called TP-7 / Selank acetate / Tuftsin analogue

A Russian-developed peptide studied for anxiety. Most of the research is Russian-language.

Official status: Not nominated for 503A compounding · Checked 2024-09-27

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Left the FDA's restricted category in September 2024 when its nomination was withdrawn. It is not on the approved compounding list.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 14

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for Selank. Unsubscribe in one click.